Entecavir-d2
目录号 : GC52261
An internal standard for the quantification of entecavir
Cas No.:142217-69-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Entecavir-d2 is intended for use as an internal standard for the quantification of entecavir by GC- or LC-MS. Entecavir is an antiviral nucleoside analog of 2'-deoxyguanosine and inhibitor of hepatitis B virus (HBV) reverse transcriptase (IC50 = 0.5 nM).1,2 It undergoes phosphorylation by cellular kinases to its active form, entecavir triphosphate.2,3 Entecavir reduces virion DNA in the culture supernatant of HepG2 2.2.15 cells infected with hepatitis B virus (HBV; EC50 = 3.75 nM).1 It reduces serum and hepatic levels of viral DNA in a duckling model of HBV infection when administered at a dose of 1 mg/kg.4 Formulations containing entecavir have been used in the treatment of chronic HBV infection.
1.Innaimo, S.F., Seifer, M., Bisacchi, G.S., et al.Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virusAntimicrob. Agents Chemother.41(7)1444-1448(1997) 2.Langley, D.R., Walsh, A.W., Baldick, C.J., et al.Inhibition of hepatitis B virus polymerase by entecavirJ. Virol.81(8)3992-4001(2007) 3.Fung, J., Lai, C.-L., Seto, W.-K., et al.Nucleoside/nucleotide analogues in the treatment of chronic hepatitis BJ. Antimicrob. Chemother.66(12)2715-2725(2011) 4.Marion, P.L., Salazar, F.H., Winters, M.A., et al.Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replicationAntimicrob. Agents Chemother.46(1)82-88(2002)
| Cas No. | 142217-69-4 | SDF | Download SDF |
| Canonical SMILES | O=C(N=C(N1)N)C2=C1N([C@@]3([H])C[C@H](O)[C@@H](CO)/C3=C([2H])/[2H])C=N2 | ||
| 分子式 | C12H13D2N5O3 | 分子量 | 279.3 |
| 溶解度 | DMSO : ≥ 44 mg/mL (158.68 mM) | 储存条件 | -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.5804 mL | 17.9019 mL | 35.8038 mL |
| 5 mM | 0.7161 mL | 3.5804 mL | 7.1608 mL |
| 10 mM | 0.358 mL | 1.7902 mL | 3.5804 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。